Key facts
- This page summarizes Ron Mayron's Form 3 filing for IceCure Medical Ltd. (ICCM).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 25 Mar 2026, 17:12.
Ron Mayron - 18 Mar 2026 Form 3 Insider Report for IceCure Medical Ltd. (ICCM)
- Reporting relationship
- Director
- Issuer ticker
- ICCM
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 25 Mar 2026, 17:12:29 UTC
- Prior SEC filing
- 03 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron Mayron
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ron Mayron filed Form 3 for IceCure Medical Ltd. (ICCM) on 25 Mar 2026.
Change
- Previous filing in this sequence was filed on 03 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001722033
Primary reporting owner
Mayron Ron
- Relationship
- Director
- Address
- 7 HA'ESHEL ST., PO BOX 3163, CAESAREA, ISRAEL
- Signature
- /s/ Ron Mayron
- Signature date
- 25 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ICCM
holding
Ordinary shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 296,631
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ICCM
holding
Derivative
Share option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary shares
- Underlying amount
- 95,295
- Exercise price
- $1.55
- Footnotes
- F2, F3
ICCM
holding
Derivative
Share option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary shares
- Underlying amount
- 25,000
- Exercise price
- $1.79
- Footnotes
- F4, F5
ICCM
holding
Derivative
Share option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary shares
- Underlying amount
- 25,000
- Exercise price
- $1.68
- Footnotes
- F6, F7
ICCM
holding
Derivative
Share option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary shares
- Underlying amount
- 110,000
- Exercise price
- $3.64
- Footnotes
- F8, F9
ICCM
holding
Derivative
Share option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary shares
- Underlying amount
- 59,295
- Exercise price
- $1.51
- Footnotes
- F10, F11
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 11 footnotes
Footnote F1
Represents (i) 10,000 ordinary shares, and (ii) 286,631 restricted share units ("RSUs") granted on May 15, 2025, 25% of which vested on July 1, 2025 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, of which 107,486 RSUs have vested and 179,631 remain unvested as of March 18, 2026.
Footnote F2
The options were granted on January 10, 2018, and vested in equal quarterly installments of 6.25% beginning on December 5, 2017. As of March 18, 2026, all 95,295 options are fully vested.
Footnote F3
The options were granted with an exercise price of NIS 4.8 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.55 per share.
Footnote F4
The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning on May 21, 2019. As of March 18, 2026, all 25,000 options are fully vested.
Footnote F5
The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share.
Footnote F6
The options were granted on October 28, 2020, 25% of which vested on October 28, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 25,000 options are fully vested.
Footnote F7
The options were granted with an exercise price of NIS 5.2128 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.68 per share.
Footnote F8
The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 110,000 options are fully vested.
Footnote F9
The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.
Footnote F10
The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 44,471 options are vested.
Footnote F11
The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.